[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocarditis-due-to-drug\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocarditis-due-to-drug":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100477643","phase-2-68gaga-pentixafor-petct-in-acute-myocardial-inflammation-100477643",false,"NCT05499637","[68Ga]Ga-PentixaFor PET\u002FCT in Acute Myocardial Inflammation","Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET\u002FCT in the Diagnosis of Three Clinical Entities of Acute Myocardial Inflammation","Inclusion Criteria:\n\n* signed written informed consent\n* male or female\n* age ≥ 18 years\n* patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I)\n* SOC clinical follow-up at the cardiology department in CHUV.\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria will lead to exclusion of the participant:\n\n* absence of a signed written informed consent\n* patients aged \\\u003C 18 years\n* claustrophobia\n* myocardial ischemia in non-invasive perfusion test or coronarography in group II and III\n* clinically unstable cardiovascular conditions, including:\n\n  * clinically unstable brady-tachyarrhythmia\n  * severe and symptomatic hypo- or hypertension with documented systolic blood pressure \\\u003C 90 mmHg or ≥220 mmHg respectively\n  * cardiogenic shock.\n* women who are pregnant or breast feeding\n* intention to become pregnant during the course of the study in group II\n* previous enrolment into the current study\n* moderate to severe renal insufficiency (GFR \\\u003C 45 mL\u002Fmin\u002F1,73 m2), with contra-indication to the administration of Gadolinium in group II and III\n* enrollment of the investigator, his\u002Fher family members, employees and other dependent persons\n* history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment\n* insufficient knowledge of project language, inability to give consent or to follow procedures\n* the patient makes use of his\u002Fher \"right not to know\" and refuses to be informed about incidental findings","ALL","18 Years",{"count":19,"type":20},69,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging.\n\nSince accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of \\[68Ga\\]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients.\n\nThe identification of a correlation between \\[68Ga\\]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.",[26,27,28],"Acute Cellular Graft Rejection","Cardiac Sarcoidosis","Myocarditis Due to Drug","RECRUITING","2026-05-05",{"date":32,"type":33},"2026-05-11","ACTUAL",{"date":35,"type":33},"2023-01-17",{"date":37,"type":20},"2027-01",{"name":39,"class":40},"John O. Prior","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100578965","biomarkers-for-clinical-classification-and-outcomes-of-immune-checkpoint-inhibitor-related-related-myocarditis-in-lung-cancer-100578965","NCT06818149","Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer","A Study on the Clinical Classification and Outcome-Related Biological Markers of Immune Checkpoint Inhibitor-Related Myocarditis in Lung Cancer Patients","Inclusion Criteria:\n\n* Pathologically confirmed lung cancer and having received at least one dose of immune checkpoint inhibitor therapy;\n* Clinically diagnosed with immune checkpoint inhibitor-related myocarditis;\n* Aged 18 years or older;\n* Voluntarily signed informed consent after being fully informed.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Presence of severe underlying cardiovascular diseases or recent acute cardiac events (e.g., myocardial infarction, severe arrhythmia);\n* Concurrent other malignancies, immunosuppressive diseases, or autoimmune diseases;\n* Inability to complete the required examinations and follow-ups specified in the study.",{"count":50,"type":20},50,"OBSERVATIONAL","This study aims to investigate the clinical classification and outcome-related biomarkers of immune checkpoint inhibitor (ICI)-related myocarditis in patients with lung cancer.A total of 50 patients with ICI-related myocarditis will be enrolled, including 25 with severe\u002Fcritical myocarditis and 25 with subclinical\u002Fmild myocarditis. Blood samples will be collected at baseline and at follow-up time points (3 days, 7 days, and before discharge). Traditional myocardial injury markers, iron metabolism-related markers, and immunological markers will be measured and compared between groups. Changes in biomarkers after treatment will also be assessed. Clinical information such as in-hospital mortality and 3-month survival rates will be integrated to develop a severity assessment model. This model aims to evaluate disease severity and prognostic risk accurately by combining biomarkers, enhancing their application in clinical management.",[54,28],"Lung Cancer",[54,56,57],"Myocarditis","Immune Checkpoint Inhibitors","2025-02-05",{"date":60,"type":33},"2025-02-10",{"date":62,"type":20},"2025-01-30",{"date":64,"type":20},"2028-12-30",{"name":66,"class":40},"Shanghai Chest Hospital"]